

# WARNER CHILCOTT LTD

## FORM 8-K

(Current report filing)

Filed 06/26/09 for the Period Ending 06/26/09

Telephone	441-295-2244
CIK	0001323854
Symbol	WCRX
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 8-K**

---

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report: June 26, 2009**  
**Date of earliest event reported: June 26, 2009**

---

**Warner Chilcott Limited**

(Exact name of registrant as specified in its charter)

---

**Bermuda**  
(State or other jurisdiction  
of incorporation)

**1 - 33039**  
(Commission File Number)

**98-0496358**  
(IRS Employer  
Identification No.)

**Unit 19 Ardee Business Park, Hale Street**  
**Ardee, Co. Louth, Ireland**  
(Address of principal executive offices, including zip code)

**+353 41 685 6983**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 8.01 Other Events .**

On June 26, 2009, the Company issued a press release announcing that it will hold its 2009 Annual General Meeting of Shareholders and a Special Court-Ordered Meeting of Shareholders on August 5, 2009. A copy of the Company's press release is filed as Exhibit 99.1 hereto and is incorporated by reference into this Item 8.01.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release issued June 26, 2009.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

W ARNER C HILCOTT L IMITED

By: /s/ Paul Herendeen

Name: Paul Herendeen

Title: Executive Vice President and Chief Financial  
Officer

Date: June 26, 2009



*NEWS RELEASE*

**Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders**

ARDEE, Ireland, June 26, 2009 – Warner Chilcott Limited announced today that it will hold its 2009 Annual General Meeting of Shareholders (the “Annual Meeting”) and a Special Court-Ordered Meeting of Shareholders (the “Special Meeting”) on August 5, 2009. At the Special Meeting, the Company’s shareholders will be asked to vote in favor of certain matters related to the proposed redomestication of the Company from Bermuda to Ireland. Subject to shareholder approval and the approval of the Supreme Court of Bermuda, the redomestication will result in the creation of a newly formed public holding company organized in, and a tax resident of, Ireland. The new company, Warner Chilcott plc, will replace Warner Chilcott Limited as the ultimate public holding company. The Annual Meeting will be held at 2:00 p.m. (local time). The Special Meeting will be held immediately following the conclusion of the Annual Meeting. Both meetings will take place at The K Club, Straffan, Co Kildare, Ireland.

A definitive proxy statement for the Annual Meeting and the Special Meeting has been filed with the Securities and Exchange Commission (the “SEC”) and is expected to be mailed on or about June 29, 2009 to all shareholders of the Company as of June 19, 2009, the record date for both the Annual Meeting and the Special Meeting. During the meetings, shareholders will vote on the proposals listed in the definitive proxy statement.

The Company does not expect the proposed redomestication will have any material impact on its financial results. The Company will, upon completion of the proposed redomestication, continue to be subject to SEC reporting requirements, and the Company’s shares will continue to be listed on the NASDAQ under the symbol “WCRX”. Additional information on the proposed redomestication, including associated benefits and risks, is contained in the definitive proxy statement.

**Important Information for Shareholders**

This communication is for informational purposes only and is not a substitute for any proxy statement and related documents that the Company has filed and may file with the SEC. The Company has filed with the SEC a definitive proxy statement and intends

---

to mail the definitive proxy statement on or about June 29, 2009 to all shareholders of Warner Chilcott as of June 19, 2009. **Shareholders are urged to read the definitive proxy statement in its entirety because it contains important information about the proposed redomestication.** The definitive proxy statement is, and other documents filed or to be filed by the Company with the SEC are, or will be, available free of charge at the SEC's web site ([www.sec.gov](http://www.sec.gov)) and at the Company's web site ([www.wcrx.com](http://www.wcrx.com)).

The Company and its directors and executive officers and other persons may be deemed participants in the solicitation of proxies from the Company's stockholders in connection with the proposed redomestication. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the Company's shareholders in connection with the proposed redomestication is set forth in the definitive proxy statement.

### **The Company**

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G

**Company Contact:** Rochelle Fuhrmann  
Investor Relations  
973-442-3281  
[rfuhrmann@wcrx.com](mailto:rfuhrmann@wcrx.com)